Articles

A randomized phase II trial of tacrolimus, mycophenolate mofetil and sirolimus after non-myeloablative unrelated donor transplantation

Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Department of Biostatistics, University of Washington, Seattle, WA, USA
Colorado Blood Cancer Institute, Denver, CO, USA
Rigshospitalet, University of Copenhagen, Denmark
Medical College of Wisconsin, Milwaukee, WI, USA
Emory University, Atlanta, GA, USA
Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, USA
University of Tübingen Medical Center, Germany
VA Puget Sound Health Care System, Seattle, WA, USA
University of Leipzig, Germany
LDS Hospital, Salt Lake City, UT, USA
University of Cologne, Germany
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA;Division of Oncology, Department of Medicine, University of Washington, Seattle, WA, USA
Vol. 99 No. 10 (2014): October, 2014 https://doi.org/10.3324/haematol.2014.108340